UCB (UCBJF) News Today $184.00 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Artisan Global Equity Fund Q3 2024 CommentaryOctober 25, 2024 | seekingalpha.comArtisan International Fund Q3 2024 CommentaryOctober 25, 2024 | seekingalpha.comBimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth StrategyOctober 18, 2024 | seekingalpha.comBarclays Keeps Their Buy Rating on UCB SA (0NZT)October 7, 2024 | markets.businessinsider.comUCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic ArthritisSeptember 30, 2024 | finance.yahoo.comUCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024September 28, 2024 | finance.yahoo.comBiogen, UCB mark late-stage trial win for autoimmune disease therapySeptember 24, 2024 | seekingalpha.comBarclays Reaffirms Their Buy Rating on UCB SA (0NZT)September 17, 2024 | markets.businessinsider.comLongboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates CoverageSeptember 11, 2024 | benzinga.comCiti Reaffirms Their Buy Rating on UCB SA (0NZT)September 2, 2024 | markets.businessinsider.comWeek In Review: UCB Sells China Drug Portfolio For $680 Million To CBCSeptember 1, 2024 | seekingalpha.comJohnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCBAugust 29, 2024 | benzinga.comUCB (OTC:UCBJF) Stock Quotes, Forecast and News SummaryAugust 25, 2024 | benzinga.comCiti Sticks to Its Buy Rating for UCB SA (0NZT)August 20, 2024 | markets.businessinsider.comDAY BY DAY Upgrades UCB (UCBJF)August 12, 2024 | msn.comUCB SA ADR (UCBJY)August 7, 2024 | investing.comUCB SA (UNC0.DU)July 31, 2024 | finance.yahoo.comUCB SA (0NZT) Gets a Hold from Kepler CapitalJuly 27, 2024 | markets.businessinsider.comWaters Corporation (WAT)July 26, 2024 | finance.yahoo.comUCB SA (UCBJF) Q2 2024 Earnings Call TranscriptJuly 26, 2024 | seekingalpha.comUCB SA goes ex dividend tomorrowApril 25, 2024 | msn.comArtisan Global Equity Fund Q1 2024 CommentaryApril 24, 2024 | seekingalpha.comArtisan International Fund Q1 2024 CommentaryApril 24, 2024 | seekingalpha.comUCB Convening Notice to the General Meeting of the Shareholders 2024March 22, 2024 | finance.yahoo.comUCB price target raised by EUR 13 at BarclaysMarch 7, 2024 | realmoney.thestreet.comUCB SA reports FY resultsFebruary 28, 2024 | msn.comStocks A-ZFebruary 10, 2024 | marketwatch.comInvestors growing more bullish on SMID cap biotech stocksFebruary 4, 2024 | msn.comUCB launches newly approved psoriasis drug Bimzelx in USNovember 14, 2023 | msn.comPost Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)November 11, 2023 | finance.yahoo.comUCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023November 10, 2023 | finance.yahoo.comBIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisOctober 18, 2023 | finance.yahoo.comUCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravisOctober 18, 2023 | finance.yahoo.comUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023October 13, 2023 | finance.yahoo.comPhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaOctober 12, 2023 | finance.yahoo.comUCB SA (OTCMKTS:UCBJF) Receives Average Rating of "Hold" from AnalystsShares of UCB SA (OTCMKTS:UCBJF - Get Free Report) have been given a consensus rating of "Hold" by the seven brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have iAugust 14, 2023 | marketbeat.comFDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in AdultsJune 27, 2023 | finance.yahoo.comChina Anti-Rheumatic Drug Markets Report 2022-2027 Featuring Pfizer, F. Hoffmann-La Roche, UCB S.A., Eli Lilly and Company, & AbbVie Inc.February 22, 2023 | finance.yahoo.comUCB SA (UCBJF)October 20, 2022 | finance.yahoo.comUCB SA (OTCMKTS:UCBJF) Given Average Recommendation of "Hold" by BrokeragesSeptember 12, 2022 | marketbeat.comUCB (OTCMKTS:UCBJF) Downgraded by Jefferies Financial GroupJefferies Financial Group downgraded shares of UCB from a "buy" rating to a "hold" rating in a report on Monday.July 25, 2022 | marketbeat.comUCB SA (OTCMKTS:UCBJF) Short Interest Up 31.0% in AprilUCB SA (OTCMKTS:UCBJF - Get Rating) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totalling 615,100 shares, an increase of 31.0% from the April 15th total of 469,500 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 6,151.0 days.May 16, 2022 | marketbeat.comHere's Why Momentum in UCB SA (UCBJF) Should Keep goingApril 25, 2022 | finance.yahoo.comWhat Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"March 31, 2022 | msn.comUCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022March 25, 2022 | finanznachrichten.deBiogen signs licensing deal with Xbrane for potential biosimilar to CimziaFebruary 7, 2022 | seekingalpha.comZGNX Jan 2022 7.000 callJanuary 23, 2022 | finance.yahoo.comWhy Zogenix Flew Higher Before Leveling Off This WeekJanuary 21, 2022 | msn.comUCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The HighlightsJanuary 19, 2022 | markets.businessinsider.comUCB Showcases Key Rheumatology Data at ACR Convergence 2021November 5, 2021 | finance.yahoo.com Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. UCBJF Media Mentions By Week UCBJF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UCBJF News Sentiment▼0.000.45▲Average Medical News Sentiment UCBJF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UCBJF Articles This Week▼00▲UCBJF Articles Average Week Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CAPS News Today LTUS News Today MYNZ News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:UCBJF) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Share UCB With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
